anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Provided are: a novel percutaneous penetration control agent for oil components, such as an ultraviolet absorbing agent and/or an antiseptic agent having a logP value of at least 2.0; and said novel percutaneous penetration control agent.　A cosmetic composition according to the present invention contains: a polymer having a structure represented by formula (1); and an oil component. In formula (1), R1, R2, and R3 each independently denote a hydrogen atom or a C1-C4 alkyl group, A denotes a C2-C4 alkylene group, and m and n each independently denote a number between 1.0 and 50. The number average molecular weight of the polymer is 10,000 or less. The IOB value of the polymer is 0.4-1.8. The oil component is an ultraviolet absorbing agent and/or an antiseptic agent having a logP value of at least 2.0.
Dihydrocodeine bitartrate is secreted into human milk. In women with normal dihydrocodeine metabolism (normal CYP2D6 activity), the amount of dihydrocodeine secreted into human milk is low and dose-dependent. However, some women are ultra-rapid metabolizers of dihydrocodeine. These women achieve higher-than-expected serum levels of dihydrocodeine’s active metabolite, dihydromorphine, leading to higher-than-expected levels of dihydromorphine in breast milk and potentially dangerously high serum dihydromorphine levels in their breastfed infants. Therefore, maternal use of dihydrocodeine can potentially lead to serious adverse reactions, including death, in nursing infants.

The risk of infant exposure to dihydrocodeine and morphine through breast milk should be weighed against the benefits of breastfeeding for both the mother and baby. Caution should be exercised when dihydrocodeine is administered to a nursing woman. If a dihydrocodeine containing product is selected, the lowest dose should be prescribed for the shortest period of time to achieve the desired clinical effect. Mothers using dihydrocodeine should be informed about when to seek immediate medical care and how to identify the signs and symptoms of neonatal toxicity, such as drowsiness or sedation, difficulty breastfeeding, breathing difficulties, and decreased tone, in their baby. Nursing mothers who are ultra-rapid metabolizers may also experience overdose symptoms such as extreme sleepiness, confusion or shallow breathing. Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of dihydrocodeine-containing products during breastfeeding (See Warnings).

Acetaminophen and caffeine are also excreted in breast milk in small amounts. Because of the potential for serious adverse reactions in nursing infants from this combination product, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Currently,the endovascular therapy of renal artery stenosis (especially atherosclerotic) remains in dispute. Some randomized control trials published in recent years (including ASTRAL and CORAL trials) showed the lack of additional benefit for renal artery revascularization compared with sole medical therapy. However,these randomized control trials presented a number of limitations including low numbers of patients and non-stringent inclusion criteria. Given clinical medical practice entering the era of big data, the large-sample real-word studies would be more objective to answer some pending issues of randomized controlled trial.Therefore,a multicenter prospective registry planned to recruit more than 5 000 patients with renal artery stenosis was carried out. This primary purpose of this study was to evaluate the safety and efficacy of renal artery revascularization in the real world. The secondary purpose was to investigate the etiologic distribution of renal artery stenosis and optimize the indications for renal artery revascularization.
Intervention Condition: Participants in this arm will take part in a brief ACT intervention delivered online via Qualtrics across 4-weeks; one session per week. The first two weeks will focus on mindfulness, with participants being invited to practice formal (i.e. 3-minute breathing exercise) and informal mindfulness practices (e.g. mindful walking, mindful drink etc.) during the week. The final two weeks will focus on values, specifically supporting participants to identify their personal values and set goals relating to these values. Participants have up to 6 weeks to complete the 4-week intervention.
In MAGNETS, sixty-four participants will be recruited from the NMVAHCS PTSD programs, Polytrauma services, and outpatient mental health clinics. At study entry (Visit #1), participants will undergo baseline demographic, behavioral, and cognitive assessment, and fMRI and diffusion tensor imaging (DTI). The data analysis team will then determine the image-based target in the right hemisphere. Participants will be randomized to either the active (n=32) or sham (n=32) group and undergo 50 sessions of iTBS (10x/day, five days). At end of treatment (Visit #2), they will repeat all baseline tests, including fMRI. One-, three- and six-month symptom levels will be obtained through phone visits (Visits #3-5) to establish longevity and stability of benefit. Repeated measures analyses will be performed on behavioral and connectivity variables, with clinical (age, duration, head injury history) and imaging (white matter fiber counts) features as covariates.
The invention that is presented in this document is called Vitacol cream.  Vitacol cream is a special product that mostly constitutes from the products of collagen and Vitamin E  oil/powder. Depending on the conditions of the skin, Vitamin D may be included. Vitamin E is commonly known in the market for its purposes as an antioxidant supplement which mostly contains natural tocopherol, which tends to help the respiratory and cardiovascular system, along with support for the brain. The present invention is in the technical field of cosmetics. More particularly, the present invention and this magnificent compounding mixture are in the technical field of restoring and improving: cellulite, scars, stretch marks, dryness, cracked cuticles, wrinkles, damaged skin, psoriasis, rashes, acne and eczema. The products effect is very powerful and precise that the results are very accurate. The compounding mixture is soothing, easily applicable and absorbs easily. The product does not cause irritation and is neither sloppy nor greasy.
At entry subjects will undergo routine laboratory and imaging assessment of their multiple myeloma. Eligible subjects will undergo steady-state apheresis to obtain large numbers of peripheral blood mononuclear cells (PBMC) for CART-BCMA manufacturing. Cryopreserved historical apheresis products collected from the patient prior to study entry are usable for CART-BCMA manufacturing if collected at an appropriately certified apheresis center and the product meets adequate mononuclear cell yields. If a historical apheresis product is not available, an apheresis procedure will be scheduled for cell procurement after study entry. The T cells will be purified from the PBMC, transduced with TCRζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration. The number of subjects who have inadequate T cell collections, expansion or manufacturing compared to the number of subjects who have CAR T cells successfully manufactured will be recorded; feasibility of product manufacturing is not expected to be problematic in this patient population.
Systems and methods for forecasting and/or explaining health metrics are provided. In some embodiments, for example, a method for informing a user of at least one health factor contributing to a predicted health metric comprises receiving health data of the user, and calculating a plurality of features based on the health data. The features can be categorized into a plurality of feature groups. The method further includes generating a prediction of a health metric of the user by inputting the features into a machine learning model. The method can also include identifying at least one contributing health factor by selecting at least one feature group that provides a threshold contribution to the prediction, and determining a health factor associated with the at least one feature group. The method can include outputting a notification for the user including the prediction and the at least one contributing health factor.
VA ECLS is used as a temporary circulatory support during cardiogenic shock and refractory cardiac arrest. Complications of VA ECLS include hemorrhagic, infectious and ischemic events. VA ECLS requires arterial and venous canules which are frequently positioned in the femoral artery and vein, which carries the risk of lower limb ischemia due to retrograde flow and obstruction of the femoral artery lumen. VA ischemia during VA ECLS is frequent (11-52%) and requires the use of reperfusion canula in the femoral common artery on VA ECLS implantation in a primary prevention strategy, before lower limb ischemia occurs. Even with this strategy, lower limb ischemia can occur due to arterial thrombosis, arterial spasm or insufficient blood flow through the reperfusion canula. Lower limb complications are prevented by monitoring of regional oxygen saturation, control of the reperfusion canula position (ultrasound, angiography) and rapid management when lower limb ischemia is suspected. There are no clear recommendations regarding prevention of lower limb complications during VA ECLS and arterial angiography has been described to diagnose ischemic events and evaluate the effectiveness of an intervention such as injection of vasodilators. This study is a prospective evaluation of a strategy to prevent lower limb complications during VA ECLS with a systematic arterial angiography on VA ECLS implantation and when lower limb ischemia is suspected (regional oxygen tissue saturation \<50% or a differential \>15% between both lower limbs) in addition to continuous NIRS monitoring of lower limbs during VA ECLS.
PCT No. PCT/GB95/00042 Sec. 371 Date Jul. 11, 1996 Sec. 102(e) Date Jul. 11, 1996 PCT Filed Jan. 11, 1995 PCT Pub. No. WO95/19187 PCT Pub. Date Jul. 20, 1995A conjugate comprises a linear or cyclic synthetic peptide of 3-50 amino acids linked via one of its carboxyl groups and optionally via a linking group, to a polydentate metal chelating group, with the result that endo- or exo-peptidase metabolism of the peptide is substantially inhibited, with the provisos that: a) the peptide chain contains a biological targeting sequence which is biologically active; b) when the spacer is absent the metal chelating group does not comprise solely peptide moieties; c) the metal chelating group does not contain thiol donors. A complex of the conjugate with a metal atom chelated by the metal chelating group is useful in medicine.
A method of inducing the expression of one or more bone morphogenetic proteins and/or transforming growth factor-.beta. proteins in a cell is described. The method includes transfecting a cell with an isolated nucleic acid comprising a nucleotide sequence encoding a LIM mineralization protein operably linked to a promoter. The one or more bone morphogenetic proteins can be BMP-2, BMP-4, BMP-6, BMP-7 or combinations thereof. The transforming growth factor-.beta.  protein can be transforming growth factor- .beta.1 protein (TGF- .beta.1).  Transfection may be accomplished ex vivo or in vivo by direct injection of virus or naked DNA, or by a nonviral vector such as a plasmid. The method can be used to induce bone formation in osseous cells or to stimulate proteoglycan and/or collagen production in cells capable of producing proteoglycyan and/or collagen (e.g., intervertebral disc cells).
Tablets

Take WELCHOL tablets with a meal and liquid. For patients with difficulty swallowing tablets, use WELCHOL for oral suspension [see Warnings and Precautions (5.2)]. 

For Oral Suspension

To prepare, empty the entire contents of one packet into a glass or cup. Add 1 cup (8 ounces) of water, fruit juice, or diet soft drinks. Stir well and drink. Take WELCHOL oral suspension with meals. Do not take WELCHOL oral suspension in its dry form. Due to tablet size, WELCHOL for oral suspension is recommended for use in the pediatric population.
Allergenic extracts for diagnostic testing produce erythema or erythema and wheal reactions in patients with significant IgE-mediated sensitivity to the relevant allergen. This allergic inflammatory response, although not completely understood, is thought to begin with the reaction of antigen with IgE on the surface of basofils, or mast cells, which initiates a series of biochemical events resulting in the production of histamine and other mediators. These, in turn, produce the immediate-type “wheal and flare” skin reaction. The more mediator released, the larger the reaction. Because of a variety of factors, including the types of allergen extracts, delayed skin reactions can occur and usually disappear within a couple of days. The type of extract, size of the reaction and timing of the reaction are all factors used in determining a patient’s sensitivity to an allergen. 

Allergen immunotherapy (also known as desensitization, hyposensitization, allergy vaccination, or allergy shots) involves treating a patient with increasing dosage of the allergens to which he is allergic, eventually reaching a dose plateau whereas the patient experiences an increased tolerance upon re-exposure to the allergens. The patient may or may not need to receive continued treatment to demonstrate the desensitization. The exact mechanisms of reaction of desensitization with allergens, which involve the allergen, IgE and IgG antibodies, mast cells and basophils and possibly other mediators, are not completely understood. However, efficacy has been shown in numerous well-controlled studies using specific common allergens.

The goals of allergen immunotherapy are to decrease the production of IgE antibodies, initiate the production of IgG antibodies and stabilize mast cells and basophils. Overproduction of IgE in response to an allergen can induce other cells, particularly mast cells and basophils, to initiate a complex chain reaction that results in allergy symptoms. Numerous IgE receptor sites are located on mast cells as well as basophil cells. These cells are among the first cells to be encountered by the antigen. They contain potent chemical mediators (histamine and leukotriene, for example) of inflammation that are released when IgE and a specific allergen cross-link on the cell surface. The release of the chemical mediators results in inflammation and allergy symptoms. As a response to immunotherapy, the production of IgG is believed to work by blocking IgE from binding to mast cells and basophils. Thus IgG, the blocking antibody, may prevent the release of chemical mediators that produce allergy symptoms.
VX-509 is an oral, selective Janus kinase 3 (JAK3) inhibitor being developed by Vertex. In autoimmune diseases, JAK3 is an essential component of the immune signaling cascade. This cascade ultimately contributes to abnormal immune response that results in chronic inflammation and, in the case of rheumatoid arthritis (RA), irreversible damage to cartilage and bones. Selective inhibition of JAK3 offers a new disease modifying approach to the treatment of RA.

This study will follow a "treat to target" (T2T) paradigm. T2T strategies have been followed in non-rheumatologic fields for decades. T2T trials have been conducted for RA from the late 1990's, and have substantiated the concept that treating to a target is associated with a better outcome than standard of care treatment. This has led to recommendations by experts to use T2T strategies in clinical practice.
Bevacizumab is a common strategy for the treatment of recurrent glioblastoma. Survival status is a crucial issue for patients with recurrent glioblastoma, and the apparent diffusion coefficient (ADC) values of the lower Gaussian curve have been reported to have the potential to predict prognosis in recurrent glioblastoma. In the present study, we aimed to clarify the survival prediction of ADC values in patients with recurrent glioblastoma receiving bevacizumab treatment through a systematic review and meta-analysis of randomized clinical trials, comparing ADC values higher than the cut-off values with those lower than the cut-off values to determine which type of ADC values can be associated with significant survival benefits. Different survival indicators were analyzed, including overall survival (OS) and progression-free survival (PFS). Ten studies with a total of 782 patients with recurrent glioblastoma were included. The focused outcomes were OS and PFS. Our results showed that ADC values lower than the cut-off values were associated with significant benefits for OS status compared with ADC values higher than the cut-off values. Similar significant benefits were observed for PFS. The meta-analysis results suggest that ADC values lower than the cut-off values might be associated with significant benefits for OS and PFS when compared with ADC values higher than the cut-off values. However, bias in relation to the different stages of recurrent glioblastoma and different types, doses, and regimens of bevacizumab should not be ignored.
Because azacitidine is potentially hepatotoxic in patients with severe pre-existing hepatic impairment, caution is needed in patients with liver disease. Patients with extensive tumor burden due to metastatic disease have been reported to experience progressive hepatic coma and death during azacitidine treatment, especially in such patients with baseline albumin <30 g/L. Azacitidine is contraindicated in patients with advanced malignant hepatic tumors [see Contraindications (4.1)]. Monitor liver chemistries prior to initiation of therapy and with each cycle. 

Safety and effectiveness of azacitidine for injection in patients with MDS and hepatic impairment have not been studied as these patients were excluded from the clinical trials.

Pediatric use information is approved for Celgene Corporation's Vidaza (azacitidine for injection). However, due to Celgene Corporation's marketing exclusivity rights, this drug product is not labeled with that information.
A solution for ophthalmic lens comprises a first hyaluronic acid or its salt, a second hyaluronic acid or its salt, and a solvent. The molecular weight of the first hyaluronic acid or its salt is between 100 kDA and 6000 kDA. The molecular weight of the second hyaluronic acid or its salt is less than 100 kDA. The solution is applied to the surface of the ophthalmic lens. Before the solution is applied to the ophthalmic lens, the contact angle of the ophthalmic lens is C1. After the solution is applied to the ophthalmic lens and used for a period of time, the contact angle of the ophthalmic lens is C2 and the solution satisfies the following range of 16% < (C1-C2)/C1*100% < 61%. In this way, when the solution is used in the ophthalmic lens, it can prolong the effect of the ophthalmic lens in maintaining rehydration and moisture retention so that the wearer can still maintain the comfortable wearing effect after wearing the ophthalmic lens for a long time. The solvent is a buffer solution. The total content of the first hyaluronic acid or its salt and the second hyaluronic acid or its salt is 0.005 wt% to 1 wt% of the total content of the solution. The content of the first hyaluronic acid or its salt is 1/3 to 3 times the content of the second hyaluronic acid or its salt. The first hyaluronic acid or its salt and the second hyaluronic acid or its salt can be sodium hyaluronate, potassium hyaluronate or a combination thereof. The solution for ophthalmic lens comprises cellulose mixed ether.
The invention provides a multicolor perylene bisimide fluorescent dye and a synthesis method and application thereof. The multi-color perylene imide fluorescent dye has the advantages of few synthesis steps, simple preparation method and high yield. The obtained fluorescent dye maintains the excellent optical property of the perylene bisimide, further improves the light stability of the perylene bisimide fluorescent dye, expands the fluorescence emission wavelength to 732nm (ethanol), and reaches the near infrared region. In addition, the dye has low biological toxicity and good biocompatibility, and can be specially used in various living cellsThe lipid drops are marked by different properties, and different fluorescent dyes can be matched to meet multicolor fluorescence imaging. The invention has great application prospect in the field of lipid drop fluorescence imaging. Formula (I).
This was a 6-month pilot intervention study of self-identifying Maori participants in a randomised control trial conducted in Dunedin and Invercargill. The study consisted of three, two month phases and was conducted over a period of six months. Participants meeting all the inclusion criteria were randomised into three groups: moderate carbohydrate-high protein (MCHP), high carbohydrate-high fibre (HCHF) or a control group. Those randomised to the experimental diets were recommended an energy intake based on their current BMI levels. The aim of phase one was to achieve weight loss with weekly advice and support from the research team. The aim of phase two was for weight maintenance with continued weekly advice and support. Phase three consisted of a weight maintenance phase without support. Those in the control group were instructed to follow their own self selected diet plan.

Outcome was determined by examining surrogate clinical endpoints. The clinical endpoints included the following recorded measurements of anthropometric measurements, bioelectrical impedance measurements, profile of mood state questionnaires, activity questionnaires, and three day diet records were collected at 0, 2, 4 and 6 month periods. Biochemical measures of lipid profile, fasting insulin and glucose, liver functions and uric acid levels were also conducted.
The invention relates to anti-wrinkle control cream and preparation method thereof. Each part of control cream contains component A, component B and component C. Component A comprises 2-3% of sodium lactyl benhenate, 3.0-3.5% of hexyldecyloctadecanol, 2.6-3% of glycerol stearate, 6-7% of isopropyl palmitate, 6-8% of sunflower seed oil; component B comprises 3-4% of glycerol and deionized water; and component C comprises 0.2-0.3% of hydantoin, 2-3% of ascorbyl magnesium phosphate and 4-6% of lecithin. The preparation method includes that the component A is compounded and heated to 80 DEG C, and the component B is compounded and heated to 80 DEG C. The component A is added into the component B and cooled at 35 DEG C, and hydantoin, ascorbyl magnesium phosphate and lecithin are added. The control cream is a white emulsion delivering the ascorbyl magnesium phosphate and lecithin to skin. The control cream can be directly coated on the face after cleaning and lightly applied to be uniform. The invention can prevent and resist skin ageing, promote blood circulation, maintain the face skin to be elastic and reduce wrinkles on face skin.